Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

Back to Item »

Pfizer Negotiates Global Rights to GlycoMimetics’ Phase II Sickle Cell Crisis Drug

Deal valued at $340 million gives Pfizer rights to all potential applications of GMI-1070, a pan-selectin antagonist.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »